Patient characteristics
| Parameter . | n . | % . |
|---|---|---|
| Sample size | ||
| All patients aSCT in CR1 | 97 | 100 |
| Age, y | ||
| Median | 41 | |
| Range | 18-64 | |
| Sex | ||
| Male | 58 | 60 |
| Female | 39 | 40 |
| Breakpoint BCR-ABL | ||
| M-Bcr-Abl (b2a2, b3a2) | 33 | 34 |
| m-Bcr-Abl (e1a2) | 52 | 54 |
| e1a3/b2a3 | 2/1 | 3 |
| n.a. | 9 | 9 |
| WBCs, ×109/L | ||
| <30 | 49 | 51 |
| >30 | 46 | 47 |
| n.a. | 2 | 2 |
| SCT donor type | ||
| Matched SIB/UD | 72 (27/45) | 74 |
| Mismatched SIB/UD | 21 (1/20) | 22 |
| Haplo | 1 | 1 |
| n.a. | 3 | 3 |
| Stem cell source | ||
| PBSCT | 92 | 95 |
| BM | 4 | 4 |
| n.a. | 1 | 1 |
| Conditioning regimen | ||
| TBI based (+Cy/+VP16/+other) | 80 | 82 |
| No TBI | 16 | 17 |
| n.a. | 1 | 1 |
| Imatinib therapy | ||
| From induction I | 69 | 71 |
| After induction I (day 24) | 23 | 24 |
| After induction II | 5 | 5 |
| Early clinical response | ||
| CR after IP1 (d26) | 78 | 81 |
| No CR after IP1 (d26) | 9 | 9 |
| n.a. | 10 | 10 |
| Follow-up (range), mo | ||
| Median follow-up OS | 35 (5.4-114.4) | |
| Median follow-up DFS and REM | 20.5 (0.6-108.3) |
| Parameter . | n . | % . |
|---|---|---|
| Sample size | ||
| All patients aSCT in CR1 | 97 | 100 |
| Age, y | ||
| Median | 41 | |
| Range | 18-64 | |
| Sex | ||
| Male | 58 | 60 |
| Female | 39 | 40 |
| Breakpoint BCR-ABL | ||
| M-Bcr-Abl (b2a2, b3a2) | 33 | 34 |
| m-Bcr-Abl (e1a2) | 52 | 54 |
| e1a3/b2a3 | 2/1 | 3 |
| n.a. | 9 | 9 |
| WBCs, ×109/L | ||
| <30 | 49 | 51 |
| >30 | 46 | 47 |
| n.a. | 2 | 2 |
| SCT donor type | ||
| Matched SIB/UD | 72 (27/45) | 74 |
| Mismatched SIB/UD | 21 (1/20) | 22 |
| Haplo | 1 | 1 |
| n.a. | 3 | 3 |
| Stem cell source | ||
| PBSCT | 92 | 95 |
| BM | 4 | 4 |
| n.a. | 1 | 1 |
| Conditioning regimen | ||
| TBI based (+Cy/+VP16/+other) | 80 | 82 |
| No TBI | 16 | 17 |
| n.a. | 1 | 1 |
| Imatinib therapy | ||
| From induction I | 69 | 71 |
| After induction I (day 24) | 23 | 24 |
| After induction II | 5 | 5 |
| Early clinical response | ||
| CR after IP1 (d26) | 78 | 81 |
| No CR after IP1 (d26) | 9 | 9 |
| n.a. | 10 | 10 |
| Follow-up (range), mo | ||
| Median follow-up OS | 35 (5.4-114.4) | |
| Median follow-up DFS and REM | 20.5 (0.6-108.3) |
BM, bone marrow derived stem cell transplantation; Cy, cyclophosphamide; DFS, disease-free survival; haplo, haploident; IP1, induction phase 1; n.a., not available; OS, overall survival; PBSCT, peripheral blood derived stem cell transplantation; REM, remission duration; SIB, sibling; TBI, total body irradiation; UD, unrelated donor; VP16, etoposide; WBCs, white blood cells.